Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 6511 AL 6525

Regarding the ghosts of home care

Panasci J.

Care Manag J. 2010;11(2):91-2. doi: 10.1891/1521-0987.11.2.91.

The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease

Mitchell RA, Herrmann N, Lanctôt KL.

CNS Neurosci Ther. 2011 Oct;17(5):411-27. doi: 10.1111/j.1755-5949.2010.00161.x. Epub 2010 Jun 16.

The dramatic effects of Galantamine in a patient with early-onset Alzheimer's disease

Dev H, Agius M, Zaman R.

Psychiatr Danub. 2010 Jun;22(2):367-9.

[Memantine for treatment of behavioural disturbances and psychotic symptoms in moderate to moderately severe Alzheimer dementia: a naturalistic study in outpatient services in Austria]

Schmidt R, Baumhackl U, Berek K, Brücke T, Kapeller P, Lechner A, Rainer M, Stögerer EM.

Neuropsychiatr. 2010;24(2):125-31.

Memantine-related psychotic symptoms in a patient with bipolar disorder

Canan F, Ataoglu A.

J Clin Psychiatry. 2010 Jul;71(7):957. doi: 10.4088/JCP.09l05802gry.

[Drug therapy for Alzheimer's disease]

Shoji M.

Brain Nerve. 2010 Jul;62(7):777-85.

[Caring for patients with Alzheimer's disease]

Hirono N.

Brain Nerve. 2010 Jul;62(7):797-802.

Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality

Ballard C, Creese B, Corbett A, Aarsland D.

Expert Opin Drug Saf. 2011 Jan;10(1):35-43. doi: 10.1517/14740338.2010.506711. Epub 2010 Aug 5.

Third degree heart block following intramuscular ziprasidone

Tambyraja R, Strawn JR.

Schizophr Res. 2011 Feb;125(2-3):302-3. doi: 10.1016/j.schres.2010.07.015. Epub 2010 Aug 7.

Technology-aided verbal instructions to help persons with mild or moderate Alzheimer's disease perform daily activities

Lancioni GE, Singh NN, O'Reilly MF, Sigafoos J, Tatulli E, Rigante V, Zonno N, Perilli V, Pinto K, Minervini MG.

Res Dev Disabil. 2010 Nov-Dec;31(6):1240-50. doi: 10.1016/j.ridd.2010.07.021. Epub 2010 Aug 8.

Cognitive intervention in Alzheimer disease

Buschert V, Bokde AL, Hampel H.

Nat Rev Neurol. 2010 Sep;6(9):508-17. doi: 10.1038/nrneurol.2010.113. Epub 2010 Aug 17.

Why are drug trials in Alzheimer's disease failing?

Lancet. 2010 Aug 28;376(9742):658. doi: 10.1016/S0140-6736(10)61316-5.

Donepezil treatment in Alzheimer's disease patients with and without cerebrovascular lesions: a preliminary report

Na HR, Kim S, Choi SH, Yang DW, Bae HJ, Kim JE, Park MY, Shim YS, Kim BK, Kwon JC, Yoo BG, Kim BC, Lee JS.

Geriatr Gerontol Int. 2011 Jan;11(1):90-7. doi: 10.1111/j.1447-0594.2010.00649.x. Epub 2010 Sep 3.

Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial

Akhondzadeh S, Sabet MS, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SSh, Yousefi MH, Alimardani R, Jamshidi A, Zare F, Moradi A.

J Clin Pharm Ther. 2010 Oct;35(5):581-8. doi: 10.1111/j.1365-2710.2009.01133.x.

EFNS guidelines for the diagnosis and management of Alzheimer's disease

Hort J, O'Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P; EFNS Scientist Panel on Dementia.

Eur J Neurol. 2010 Oct;17(10):1236-48. doi: 10.1111/j.1468-1331.2010.03040.x.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias